<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:normal;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-indent:-.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.6in;
	text-indent:-.6in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;
	text-decoration:underline;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.7in;
	text-indent:-.7in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:#365F91;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.9in;
	text-indent:-.9in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.1in;
	text-indent:-1.1in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.2in;
	text-indent:-1.2in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Annotationtext";
	mso-style-link:"Comment Text Char\,Annotationtext Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Char";
	mso-style-link:"Caption Char\,Char Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.05in;
	text-indent:-1.05in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.MsoCommentReference
	{mso-style-name:"Comment Reference\,Annotationmark";}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.25in;
	margin-bottom:0in;
	margin-left:-.9pt;
	text-indent:.9pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:red;
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-name:"List Paragraph\,List Paragraph 1";
	mso-style-link:"List Paragraph Char\,List Paragraph 1 Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Annotationtext Char";
	mso-style-link:"Comment Text\,Annotationtext";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	line-height:13.0pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.CDSOptionalconcepts, li.CDSOptionalconcepts, div.CDSOptionalconcepts
	{mso-style-name:"CDS Optional concepts";
	mso-style-link:"CDS Optional concepts Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.CDSOptionalconceptsChar
	{mso-style-name:"CDS Optional concepts Char";
	mso-style-link:"CDS Optional concepts";
	font-family:"Times New Roman",serif;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-style:italic;
	text-decoration:underline;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
span.StyleEmphasisTimesNewRomanBoldBoldNotItalicBlack
	{mso-style-name:"Style Emphasis + Times New Roman Bold Bold Not Italic Black";
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	color:#365F91;}
span.ListParagraphChar
	{mso-style-name:"List Paragraph Char\,List Paragraph 1 Char";
	mso-style-link:"List Paragraph\,List Paragraph 1";
	font-family:"Calibri",sans-serif;}
p.PIHeading1, li.PIHeading1, div.PIHeading1
	{mso-style-name:"PI Heading 1";
	mso-style-link:"PI Heading 1 Char";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.PIHeading1Char
	{mso-style-name:"PI Heading 1 Char";
	mso-style-link:"PI Heading 1";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.Body-Text, li.Body-Text, div.Body-Text
	{mso-style-name:Body-Text;
	mso-style-link:"Body-Text Zchn";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
span.Body-TextZchn
	{mso-style-name:"Body-Text Zchn";
	mso-style-link:Body-Text;
	font-family:"Arial",sans-serif;}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	mso-style-link:"Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.ParagraphChar
	{mso-style-name:"Paragraph Char";
	mso-style-link:Paragraph;
	font-family:"Times New Roman",serif;}
p.tableparagraph, li.tableparagraph, div.tableparagraph
	{mso-style-name:"table paragraph";
	mso-style-link:"table paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:5.05pt;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;
	letter-spacing:-.05pt;}
span.tableparagraphChar
	{mso-style-name:"table paragraph Char";
	mso-style-link:"table paragraph";
	font-family:"Calibri",sans-serif;
	letter-spacing:-.05pt;}
p.C-BodyText, li.C-BodyText, div.C-BodyText
	{mso-style-name:"C-Body Text";
	mso-style-link:"C-Body Text Char1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.C-BodyTextChar1
	{mso-style-name:"C-Body Text Char1";
	mso-style-link:"C-Body Text";
	font-family:"Times New Roman",serif;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Cambria",serif;
	color:#365F91;}
p.anything, li.anything, div.anything
	{mso-style-name:anything;
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.Mention1
	{mso-style-name:Mention1;
	color:#2B579A;
	background:#E6E6E6;}
span.CaptionChar
	{mso-style-name:"Caption Char\,Char Char";
	mso-style-link:"Caption\,Char";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.UnresolvedMention1
	{mso-style-name:"Unresolved Mention1";
	color:#605E5C;
	background:#E1DFDD;}
span.normaltextrun
	{mso-style-name:normaltextrun;}
span.eop
	{mso-style-name:eop;}
span.scxw150463701
	{mso-style-name:scxw150463701;}
span.scxw99689742
	{mso-style-name:scxw99689742;}
p.pstyle7, li.pstyle7, div.pstyle7
	{mso-style-name:p_style7;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.style1
	{mso-style-name:style1;}
span.jlqj4b
	{mso-style-name:jlqj4b;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Calibri",sans-serif;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=DE><img width=21
height=18 id="Picture 1" src="Comirnaty-h-5735-en_files/image001.png"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicinal product is subject
to additional monitoring. This will allow quick identification of new safety
information. Healthcare professionals are asked to report any suspected adverse
reactions. See section 4.8 for how to report adverse reactions.<span
style='color:#00B050'> </span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Comirnaty </span><span
lang=EN-GB>concentrate for dispersion for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>COVID-19 mRNA
Vaccine (nucleoside modified)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This is a
multidose vial and must be diluted before use. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One vial
(0.45&nbsp;mL) contains 6 doses of 0.3&nbsp;mL after dilution, see sections 4.2
and 6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 dose (0.3&nbsp;mL)
contains 30&nbsp;micrograms of COVID-19 mRNA Vaccine (embedded in lipid
nanoparticles). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Single-stranded, 5’-capped messenger RNA
(mRNA) produced using a cell-free <i>in vitro</i> transcription from the
corresponding DNA templates, encoding the viral spike (S) protein of
SARS-CoV-2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concentrate for dispersion
for injection (sterile concentrate).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The vaccine is a
white to off-white frozen dispersion (pH: 6.9 - 7.9).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>4.       CLINICAL
PARTICULARS</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Comirnaty is indicated for active immunisation
to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16&nbsp;years of
age and older. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The use of this vaccine should be in
accordance with official recommendations.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2     Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Individuals
16 years of age and older</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Comirnaty is administered intramuscularly
after dilution as a course of 2 doses (0.3&nbsp;mL each). It is recommended to
administer the second dose 3 weeks after the first dose (see sections 4.4 and
5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no data available on the
interchangeability of Comirnaty with other COVID-19 vaccines to complete the
vaccination course. Individuals who have received 1 dose of Comirnaty should
receive a second dose of Comirnaty to complete the vaccination course. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of Comirnaty<span style='color:#00B050'> </span>in
children and adolescents aged less than 16 years of age have not yet been
established. Limited data are available.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Elderly population</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>No dosage adjustment is required in elderly individuals &#8805;&nbsp;65
years of age.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Comirnaty should be administered intramuscularly after <u>dilution</u>
(see section 6.6). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>After dilution, vials of Comirnaty contain six doses of 0.3 mL of
vaccine. In order to extract six doses from a single vial, low dead-volume syringes
and/or needles should be used. The low dead-volume syringe and needle
combination should have a dead volume of no more than 35&nbsp;microlitres. If
standard syringes and needles are used, there may not be sufficient volume to
extract a sixth dose from a single vial. Irrespective of the type of syringe
and needle:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Each dose must contain 0.3&nbsp;mL of vaccine.  </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If the amount of vaccine remaining in the vial
cannot provide a full dose of 0.3&nbsp;mL, discard the vial and any excess
volume. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not pool excess vaccine from multiple vials.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The preferred site is the deltoid muscle of the upper arm.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not inject
the vaccine intravascularly, subcutaneously or intradermally. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The vaccine
should not be mixed in the same syringe with any other vaccines or medicinal
products.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For precautions
to be taken before administering the vaccine, see section 4.4.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For instructions
regarding thawing, handling and disposal of the vaccine, see section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="_Hlk55810320"><span lang=EN-GB>Hypersensitivity to the active
substance or to any of the excipients listed in section 6.1.</span></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Traceability </span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In order to improve the traceability of biological medicinal
products, the name and the batch number of the administered product should be
clearly recorded.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name="OLE_LINK3"><u><span lang=EN-GB>General recommendations</span></u></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hypersensitivity and anaphylaxis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Events of
anaphylaxis have been reported. Appropriate medical treatment and supervision
should always be readily available in case of an anaphylactic reaction
following the administration of the vaccine. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Close
observation for at least 15 minutes is recommended following vaccination. </span><span
lang=EN-GB>A second dose of the vaccine should not be given to those who have
experienced anaphylaxis to the first dose of Comirnaty.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Anxiety-related reactions</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Anxiety-related reactions, including vasovagal reactions (syncope),
hyperventilation or stress</span><span lang=EN-GB style='font-family:"Cambria Math",serif'>&#8208;</span><span
lang=EN-GB>related reactions may occur in association with vaccination as a
psychogenic response to the needle injection. It is important that precautions
are in place to avoid injury from fainting.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Concurrent illness</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vaccination
should be postponed in individuals suffering from acute severe febrile illness
or acute infection. The presence of a minor infection and/or low-grade fever
should not delay vaccination.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Thrombocytopenia and coagulation
disorders</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with other
intramuscular injections</span><span lang=EN-GB>, the vaccine should be given
with caution in individuals receiving anticoagulant therapy or those with
thrombocytopenia or any coagulation disorder (such as haemophilia) because
bleeding or bruising may occur following an intramuscular administration in
these individuals.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Immunocompromised individuals</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy, safety
and immunogenicity of the vaccine has not been assessed in immunocompromised
individuals, including those receiving immunosuppressant therapy. The efficacy
of Comirnaty may be lower in immunosuppressed individuals.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Duration of
protection</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The duration of
protection afforded by the vaccine is unknown as it is still being determined
by ongoing clinical trials.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Limitations
of vaccine effectiveness</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As with any
vaccine, vaccination with Comirnaty may not protect all vaccine recipients.
Individuals may not be fully protected until 7 days after their second dose of
vaccine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This vaccine contains less than 1&nbsp;mmol
potassium (39&nbsp;mg) per dose, that is to say essentially ‘potassium&#8209;free’.
</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This vaccine contains less than 1&nbsp;mmol
sodium (23&nbsp;mg) per dose, that is to say essentially ‘sodium&#8209;free’.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5</span></b><b><span
lang=EN-GB>     </span><span lang=EN-GB>Interaction with other medicinal
products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No interaction
studies have been performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of Comirnaty with other vaccines has not been studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6     Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience with use of
Comirnaty in pregnant women. Animal studies do not indicate direct or indirect
harmful effects with respect to pregnancy, embryo/foetal development,
parturition or post-natal development (see section 5.3). Administration of
Comirnaty in pregnancy should only be considered when the potential benefits
outweigh any potential risks for the mother and foetus.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>It is unknown
whether Comirnaty is excreted in human milk. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=Default style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Animal studies do not indicate direct or
indirect harmful effects with respect to reproductive toxicity (see section
5.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7     Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Comirnaty has
no or negligible influence on the ability to drive and use machines. However,
some of the effects mentioned under section&nbsp;4.8 may temporarily affect the
ability to drive or use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Summary of safety profile</span></u></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;background:white'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black;background:white'>The safety of </span><span lang=EN-GB
style='font-size:11.0pt'>Comirnaty<span style='color:black;background:white'>
was evaluated in participants </span>16 <span style='color:black;background:
white'>years of age and older in 2 clinical studies that included 21,744
participants that have received at least one dose of Comirnaty. </span></span></p>

<p class=MsoNormal style='background:white'><span lang=EN-GB style='background:
white'>&nbsp;</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;color:black;
background:white'>In Study 2, a total of 21,720 participants 16 years of age or
older received at least 1 dose of </span><span lang=EN-GB style='font-size:
11.0pt'>Comirnaty<span style='color:black;background:white'> and a total of
21,728 participants 16 years of age or older received placebo <a
name="_Hlk59040524">(including 138 and 145&nbsp;adolescents 16 and 17 years of
age in the vaccine and placebo groups, respectively)</a>. A total of 20,519&nbsp;participants
16 years of age or older received 2 doses of Comirnaty. </span></span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;background:white'>&nbsp;</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;color:black;
background:white'>At the time of the analysis of Study 2, a total of 19,067 (9,531
Comirnaty and 9,536 placebo) participants 16 years of age or older were
evaluated for safety for at least 2 months after the second dose of </span><span
lang=EN-GB style='font-size:11.0pt'>Comirnaty. This included a total of 10,727 (5,350
Comirnaty and 5,377 placebo) participants 16 to 55 years of age and a total of
8,340 (4,181 Comirnaty and 4,159 placebo) participants 56 years and older.</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black;background:white'>The </span><span lang=EN-GB
style='font-size:11.0pt'>most frequent <span style='color:black;background:
white'>adverse reactions in participants 16 years of age and older were injection
site pain (&gt;</span>&nbsp;<span style='color:black;background:white'>80%),
fatigue (&gt;</span>&nbsp;<span style='color:black;background:white'>60%),
headache (&gt;</span>&nbsp;<span style='color:black;background:white'>50%), myalgia
</span>and<span style='color:black;background:white'> chills (&gt;</span>&nbsp;<span
style='color:black;background:white'>30%), arthralgia (&gt;</span>&nbsp;<span
style='color:black;background:white'>20%),</span> <span style='color:black;
background:white'>pyrexia</span> and injection site swelling (&gt;&nbsp;10%)<span
style='color:black;background:white'> and were usually mild or moderate in
intensity and resolved within a few days after vaccination. A slightly lower
frequency of reactogenicity events was associated with greater age.</span></span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Tabulated list of adverse reactions from clinical studies</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
reactions observed during clinical studies are listed below according to the
following frequency categories: </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very common
(&#8805;&nbsp;1/10), </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10), </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon
(&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100), </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Rare (&#8805;&nbsp;1/10,000
to &lt;&nbsp;1/1,000), </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Very rare
(&lt;&nbsp;1/10,000), </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Not known
(cannot be estimated from the available data).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB>Table 1:     Adverse reactions from Comirnaty clinical
trials</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width="102%"
 style='margin-left:-.25pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=114 style='width:85.5pt;border:solid windowtext 1.0pt;padding:
   0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>System Organ Class</span></b></p>
   </td>
   <td width=84 style='width:63.0pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Very common</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>(&#8805;&nbsp;1/10)</span></b></p>
   </td>
   <td width=84 style='width:63.0pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Common</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10)</span></b></p>
   </td>
   <td width=126 style='width:94.5pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Uncommon</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>(&#8805;&nbsp;1/1,000 to &lt;&nbsp;1/100)</span></b></p>
   </td>
   <td width=96 style='width:1.0in;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Rare</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>(&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000)</span></b></p>
   </td>
   <td width=114 style='width:85.45pt;border:solid windowtext 1.0pt;border-left:
   none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Not known (cannot be estimated from the available
   data)</span></b></p>
   </td>
   <td style='border:none;padding:0in 0in 0in 0in' width=0><p class='MsoNormal'>&nbsp;</td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=114 valign=top style='width:85.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Lymphadenopathy</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=114 valign=top style='width:85.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Immune
  system disorders</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Anaphylaxis;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>hypersensitivity</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=114 valign=top style='width:85.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Insomnia</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=114 valign=top style='width:85.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nervous
  system disorders</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Headache</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Acute
  peripheral facial paralysis<sup>†</sup></span></p>
  </td>
  <td width=114 valign=top style='width:85.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=114 valign=top style='width:85.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nausea</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=114 valign=top style='width:85.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Musculoskeletal
  and connective tissue disorders</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Arthralgia;
  myalgia</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pain in
  extremity</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=114 valign=top style='width:85.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>General disorders
  and administration site conditions</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Injection
  site pain</span><span lang=EN-GB>; </span><span lang=EN-GB>fatigue; chills;
  pyrexia*; </span><span lang=EN-GB>injection site swelling</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Injection
  site redness</span></p>
  </td>
  <td width=126 valign=top style='width:94.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Malaise;
  injection site pruritus</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=114 valign=top style='width:85.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=618 colspan=7 valign=top style='width:463.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:8.55pt;text-indent:-8.55pt;line-height:
  normal;page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>* A
  higher frequency of pyrexia was observed after the 2<sup>nd</sup> dose.</span></p>
  <p class=MsoNormal style='margin-left:8.55pt;text-indent:-8.55pt;page-break-after:
  avoid'><sup><span lang=EN-GB style='font-size:10.0pt'>†   </span></sup><span
  lang=EN-GB style='font-size:10.0pt'>Throughout the safety follow-up period to
  date, acute peripheral facial paralysis (or palsy) was reported by four
  participants in the COVID-19 mRNA Vaccine group. Onset was Day 37 after
  Dose&nbsp;1 (participant did not receive Dose 2) and Days 3, 9, and 48 after
  Dose 2. No cases of acute peripheral facial paralysis (or palsy) were
  reported in the placebo group.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety
profile in 545 subjects receiving Comirnaty, that were seropositive for SARS-CoV-2
at baseline, was similar to that seen in the general population.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='background:
lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB> and
include batch/Lot number if available.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9</span></b><b><span
lang=EN-GB>     </span><span lang=EN-GB>Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overdose data is
available from 52 study participants included in the clinical trial that due to
an error in dilution received 58&nbsp;micrograms of Comirnaty. The vaccine
recipients did not report an increase in reactogenicity or adverse reactions. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the event of
overdose, monitoring of vital functions and possible symptomatic treatment is
recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: vaccines, other viral vaccines, ATC code: </span><span lang=EN-GB>J07BX03</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=Body-Text style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>The nucleoside-modified messenger RNA in Comirnaty
is formulated in lipid nanoparticles, which enable delivery of the non
replicating RNA into host cells to direct transient expression of the SARS&#8209;CoV-2
S antigen. The mRNA codes for membrane-anchored, full-length S with two point
mutations within the central helix. Mutation of these two amino acids to
proline locks S in an antigenically preferred prefusion conformation. The
vaccine elicits both neutralizing antibody and cellular immune responses to the
spike (S) antigen, which may contribute to protection against COVID-19.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Efficacy</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Study 2 is a multicentre, multinational, Phase 1/2/3 randomised, placebo-controlled,
observer-blind dose-finding, vaccine candidate selection and efficacy study in
participants 12 years of age and older. Randomisation was stratified by age: 12
through 15 years of age, 16 through 55 years of age, or 56&nbsp;years of age
and older, with a minimum of 40% of participants in the &#8805;&nbsp;56-year
stratum. The study excluded participants who were immunocompromised and those
who had previous clinical or microbiological diagnosis of COVID-19.
Participants with pre-existing stable disease, defined as disease not requiring
significant change in therapy or hospitalization for worsening disease during
the 6 weeks before enrolment, were included as were participants with known
stable infection with human immunodeficiency virus (HIV), hepatitis C virus
(HCV) or hepatitis B virus (HBV). At the time of the analysis of Study 2,
information presented is based on participants 16 years and older.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Efficacy in participants 16 years of age and older</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB style='font-size:11.0pt'>In the Phase
2/3 portion, approximately 44,000 participants were randomised equally and were
to receive 2&nbsp;doses of COVID-19 mRNA Vaccine or placebo separated by 21
days. The efficacy analyses included participants that received their second
vaccination within 19 to 42 days after their first vaccination. The majority (93.1%)
of vaccine recipients received the second dose 19 days to 23 days after Dose 1.
Participants are planned to be followed for up to 24 months after Dose 2, for
assessments of safety and efficacy against COVID-19. In the clinical study,
participants were required to observe a minimum interval of 14 days before and
after administration of an influenza vaccine in order to receive either placebo
or COVID-19 mRNA Vaccine. In the clinical study, participants were required to
observe a minimum interval of 60 days before or after receipt of blood/plasma
products or immunoglobulins within through conclusion of the study in order to
receive either placebo or COVID&#8209;19 mRNA Vaccine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The population for the analysis of the primary efficacy endpoint
included, 36,621 participants 12 years of age and older (18,242 in the COVID-19
mRNA Vaccine group and 18,379 in the placebo group) who did not have evidence
of prior infection with SARS-CoV-2 through 7 days after the second dose. In
addition, 134 participants were between the ages of 16 to 17 years of age (66
in the COVID-19 mRNA Vaccine group and 68 in the placebo group) and 1,616
participants 75 years of age and older (804 in the COVID-19 mRNA Vaccine group
and 812 in the placebo group).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><u><span lang=EN-GB>Efficacy against COVID-19 </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At the time of the primary efficacy analysis,
participants had been followed for symptomatic COVID&#8209;19 for in total 2</span><span
lang=EN-GB>,</span><span lang=EN-GB>214 person</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>years for the COVID-19 mRNA Vaccine and in total 2</span><span
lang=EN-GB>,</span><span lang=EN-GB>222&nbsp;person</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>years in the placebo group. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There were no meaningful clinical differences
in overall vaccine efficacy in participants who were at risk of severe COVID-19
including those with 1 or more comorbidities that increase the risk of severe
COVID-19 (e.g. asthma, body mass index (BMI) &#8805;&nbsp;30 kg/m<sup>2</sup>,
chronic pulmonary disease, diabetes mellitus, hypertension).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The vaccine efficacy information is
presented in Table 2.</span></p>

<p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:1.0pt;
margin-left:0in;background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB>Table 2:</span></b><span lang=EN-GB>     <b>Vaccine
efficacy – First COVID-19 occurrence from 7 days after Dose 2, by age subgroup
– participants without evidence of infection prior to 7 days after Dose 2 –
evaluable efficacy (7&nbsp;days) population</b></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=604 colspan=4 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>First
  COVID-19 occurrence from 7 days after Dose 2 in participants without evidence
  of prior SARS&#8209;CoV-2 infection*</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=141 style='width:106.1pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Subgroup</span></b></p>
  </td>
  <td width=161 valign=bottom style='width:120.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='margin-left:0in;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>COVID&#8209;19 mRNA Vaccine</span></b></p>
  <p class=tableparagraph align=center style='margin-left:0in;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>N<sup>a</sup>&nbsp;=&nbsp;18,198</span></b></p>
  <p class=tableparagraph align=center style='margin-left:0in;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Cases</span></b></p>
  <p class=tableparagraph align=center style='margin-left:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>n1<sup>b</sup></span></p>
  <p class=tableparagraph align=center style='margin-left:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Surveillance<sup> </sup>time<sup>c</sup> (n2<sup>d</sup>)</span></p>
  </td>
  <td width=161 valign=bottom style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Placebo</span></b></p>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></b></p>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>N<sup>a</sup>&nbsp;=&nbsp;18,325</span></b></p>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cases</span></b></p>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>n1<sup>b</sup></span></p>
  <p class=tableparagraph align=center style='margin-left:0in;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Surveillance<sup> </sup>time<sup>c</sup> (n2<sup>d</sup>)</span></p>
  </td>
  <td width=141 style='width:106.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Vaccine
  efficacy</span></b></p>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>%
  (95% CI)<sup>f</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=141 valign=top style='width:106.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>  All subjects<sup>e</sup></span></p>
  </td>
  <td width=161 valign=top style='width:120.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>8</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>2.214
  (17,411)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>162</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>2.222
  (17,511)</span></p>
  </td>
  <td width=141 style='width:106.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>95.0
  (90.0, 97.9)</span></p>
  </td>
 </tr>
 <tr>
  <td width=141 valign=top style='width:106.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>  16 to 64 years</span></p>
  </td>
  <td width=161 valign=top style='width:120.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>7</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.706
  (13,549)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>143</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1.710
  (13,618)</span></p>
  </td>
  <td width=141 style='width:106.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>95.1
  (89.6, 98.1)</span></p>
  </td>
 </tr>
 <tr>
  <td width=141 valign=top style='width:106.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>  65 years and older</span></p>
  </td>
  <td width=161 valign=top style='width:120.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0.508
  (3848)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>19</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0.511
  (3880)</span></p>
  </td>
  <td width=141 style='width:106.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>94.7
  (66.7, 99.9)</span></p>
  </td>
 </tr>
 <tr>
  <td width=141 valign=top style='width:106.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>  65 to 74 years</span></p>
  </td>
  <td width=161 valign=top style='width:120.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>1</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0.406
  (3074)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>14</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0.406
  (3095)</span></p>
  </td>
  <td width=141 style='width:106.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>92.9
  (53.1, 99.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width=141 valign=top style='width:106.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>  75 years and older</span></p>
  </td>
  <td width=161 valign=top style='width:120.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0.102
  (774)&nbsp;</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>5</span></p>
  <p class=tableparagraph align=center style='text-align:center'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0.106
  (785)&nbsp;</span></p>
  </td>
  <td width=141 style='width:106.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=tableparagraph align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>100.0
  (-13.1, 100.0)</span></p>
  </td>
 </tr>
 <tr>
  <td width=604 colspan=4 valign=top style='width:453.05pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Note: Confirmed cases were determined by Reverse
  Transcription-Polymerase Chain Reaction (RT&#8209;PCR) and at least 1 symptom
  consistent with COVID-19 [*Case definition: (at least 1 of) fever, new or
  increased cough, new or increased shortness of breath, chills, new or
  increased muscle pain, new loss of taste or smell, sore throat, diarrhoea or
  vomiting.]</span></p>
  <p class=tableparagraph style='margin-left:16.5pt;text-indent:-16.5pt'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>*     Participants
  who had no serological or virological evidence (prior to 7 days after receipt
  of the last dose) of past SARS-CoV-2 infection (i.e., N-binding antibody
  [serum] negative at Visit 1 and SARS-CoV-2 not detected by nucleic acid
  amplification tests (NAAT) [nasal swab] at Visits 1 and 2), and had negative
  NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose&nbsp;2
  were included in the analysis.</span></p>
  <p class=tableparagraph style='margin-left:16.5pt;text-indent:-16.5pt'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>a.    N&nbsp;=&nbsp;number
  of participants in the specified group. </span></p>
  <p class=tableparagraph style='margin-left:16.5pt;text-indent:-16.5pt'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>b.    n1&nbsp;=&nbsp;Number
  of participants meeting the endpoint definition.</span></p>
  <p class=tableparagraph style='margin-left:16.5pt;text-indent:-16.5pt'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>c.    Total
  surveillance time in 1000 person-years for the given endpoint across all
  subjects within each group at risk for the endpoint. Time period for COVID-19
  case accrual is from 7 days after Dose 2 to the end of the surveillance
  period.</span></p>
  <p class=tableparagraph style='margin-left:16.5pt;text-indent:-16.5pt'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>d.    n2&nbsp;=&nbsp;Number
  of subjects at risk for the endpoint.</span></p>
  <p class=tableparagraph style='margin-left:16.5pt;text-indent:-16.5pt'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>e.    No
  confirmed cases were identified in participants 12 to 15 years of age.</span></p>
  <p class=tableparagraph style='margin-left:16.5pt;text-indent:-16.5pt'><span
  lang=EN-GB style='font-family:"Times New Roman",serif;color:black'>f.     Confidence
  interval (CI) for vaccine efficacy is derived based on the Clopper and
  Pearson method adjusted to the surveillance time. </span><span lang=EN-GB
  style='font-family:"Times New Roman",serif;letter-spacing:0pt'>CI not
  adjusted for multiplicity.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the second primary analysis, compared to
placebo, efficacy of COVID-19 mRNA Vaccine in participants from first COVID-19
occurrence from 7 days after Dose 2 compared to participants with or without
evidence of prior infection with SARS-CoV-2 was 94.6% (95% credible interval of
89.9% to 97.3%) in participants 16&#8239;years of age and older. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Additionally, subgroup analyses of the
primary efficacy endpoint showed similar efficacy point estimates across
genders, ethnic groups, and participants with medical comorbidities associated
with high risk of severe COVID-19. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.0pt;margin-right:0in;margin-bottom:1.0pt;
margin-left:0in;page-break-after:avoid;background:white'><u><span lang=EN-GB
style='color:black'>Paediatric population</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><a name="_Hlk57011320"><span lang=EN-GB>&nbsp;</span></a></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The European Medicines Agency has </span><span lang=EN-GB>deferred</span><span
lang=EN-GB> the obligation to submit the results of studies with Comirnaty in
the paediatric population in </span><span lang=EN-GB>prevention of COVID-19 </span><span
lang=EN-GB>(see section 4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product has been authorised
under a so-called ‘conditional approval’ scheme. This means that further
evidence on this medicinal product is awaited. The European Medicines Agency
will review new information on this medicinal product at least every year and
this SmPC will be updated as necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Non-clinical data reveal no special hazard for humans based on
conventional studies of repeat dose toxicity and reproductive and developmental
toxicity.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>General
toxicity</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Rats intramuscularly administered Comirnaty (receiving 3 full human
doses once weekly, generating relatively higher levels in rats due to body
weight differences) demonstrated </span><span lang=EN-GB>some</span><u><span
lang=EN-GB> </span></u><span lang=EN-GB>injection </span><span lang=EN-GB>site oedema</span><span
lang=EN-GB> and erythema and increases in white blood cells (including
basophils and eosinophils) consistent with an inflammatory response as well as</span><span
lang=EN-GB> </span><span lang=EN-GB>vacuolation of portal hepatocytes without
evidence of liver injury. All effects were reversible.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Genotoxicity</span></u><u><span
lang=EN-GB>/Carcinogenicity</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-align:justify;text-justify:
inter-ideograph;line-height:normal'><span lang=EN-GB>Neither genotoxicity nor
carcinogenicity studies were performed. The components of the vaccine (lipids
and mRNA) are not expected to have genotoxic potential. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-align:justify;text-justify:
inter-ideograph;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Reproductive toxicity</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reproductive and developmental toxicity were
investigated in rats in a combined fertility and developmental toxicity study
where female rats were intramuscularly administered Comirnaty prior to mating
and during gestation (receiving 4 full human doses that generate relatively
higher levels in rat due to body weight differences, spanning between
pre-mating day 21 and gestational day 20). SARS&#8209;CoV-2 neutralizing
antibody responses were present in maternal animals from prior to mating to the
end of the study on postnatal day 21 as well as in foetuses and offspring. There
were no vaccine&#8209;related effects on female fertility, pregnancy, or embryo-foetal
or offspring development. No Comirnaty data are available on vaccine placental
transfer or excretion in milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.       PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
(ALC-0315)</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>2&#8209;[(polyethylene
glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>1,2-Distearoyl-sn-glycero-3-phosphocholine
(DSPC)</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>Cholesterol</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>Potassium chloride</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>Potassium dihydrogen phosphate</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>Sodium chloride</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>Disodium phosphate
dihydrate</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>Sucrose</span></p>

<p class=MsoBodyText style='margin-right:9.35pt;line-height:107%'><span
lang=EN-GB style='color:windowtext;font-style:normal'>Water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product must not be mixed with other medicinal products except those mentioned
in section 6.6. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Unopened vial</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>6&nbsp;months at
-90&nbsp;°C to -60&nbsp;°C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Once removed
from the freezer, the unopened vaccine can be stored for up to 5&nbsp;days at 2&nbsp;°C
to 8&nbsp;°C, and up to 2&nbsp;hours at temperatures up to 30&nbsp;°C, prior to
use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Once thawed, the
vaccine should not be re-frozen.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Closed-lid vial
trays containing 195 vials removed from frozen storage (&lt;&nbsp;-60&nbsp;°C)
may be at room temperature (&lt;&nbsp;25&nbsp;°C) for up to 5 minutes for
transfer between ultra-low-temperature environments. After vial trays are
returned to frozen storage following room temperature exposure, they must
remain in frozen storage for at least 2 hours before they can be removed again.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Diluted medicinal product</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Chemical and
physical in-use stability has been demonstrated for 6 hours at 2&nbsp;ºC to 30&nbsp;ºC
after dilution in sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection.
From a microbiological point of view, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the
responsibility of the user.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4</span></b><b><span lang=EN-GB>     </span><span
lang=EN-GB>Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in a
freezer at -90&nbsp;°C to -60&nbsp;°C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the original
package in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>During storage, minimise exposure to room
light, and avoid exposure to direct sunlight and ultraviolet light. </span></p>

<p class=MsoNormal><span lang=EN-GB>Thawed vials can be handled in room light
conditions.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>When you are ready to thaw or use the vaccine</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Open-lid
vial trays, or vial trays containing less than 195 vials removed from frozen
storage (&lt;&nbsp;</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#8209;</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>60&nbsp;°C) may be at
room temperature (&lt;&nbsp;25&nbsp;</span><span lang=EN-GB style='font-family:
"Times New Roman",serif'>°</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>C)
for up to 3 minutes to remove vials or for transfer between
ultra-low-temperature environments.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Once
a vial is removed from the vial tray, it should be thawed for use.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>After
vial trays are returned to frozen storage following room temperature exposure,
they must remain in frozen storage for at least 2 hours before they can be
removed again.</span></p>

<p class=MsoListParagraph style='margin-left:.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For storage
conditions after thawing and dilution of the medicinal product, see section
6.3. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5     Nature and contents
of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>2&nbsp;mL
clear multidose vial (type I glass) with a stopper (synthetic bromobutyl rubber)
and a flip-off plastic cap with aluminium seal. Each vial contains 6 doses, see
section 6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack size: 195 vials</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6     Special
precautions for disposal and other handling</span></b></a></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Handling
instructions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Comirnaty should be prepared by a
healthcare professional using aseptic technique to ensure the sterility of the
prepared dispersion.</span></p>

<p class=MsoListParagraph style='margin-left:.25in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=TableGrid1 border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=2 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
  name="_Hlk60731992"><b><span lang=EN-GB>THAWING PRIOR TO DILUTION</span></b></a></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=305 height=166
  src="Comirnaty-h-5735-en_files/image002.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>The multidose vial is stored frozen and must
  be thawed prior to dilution. Frozen vials should be transferred to an
  environment of 2&nbsp;°C to 8&nbsp;°C to thaw; a 195&nbsp;vial pack may take
  3&nbsp;hours to thaw. Alternatively, frozen vials may also be thawed for
  30&nbsp;minutes at temperatures up to 30&nbsp;°C for immediate use.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Allow the thawed vial to come to room
  temperature and gently invert it 10&nbsp;times prior to dilution. Do not
  shake.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Prior</span><span lang=EN-GB> to dilution, the
  thawed dispersion may contain white to off-white opaque amorphous particles. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=2 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>DILUTION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=299 height=288
  src="Comirnaty-h-5735-en_files/image003.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-size:12.0pt;font-family:Symbol;
  color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>The thawed vaccine must be diluted in its
  original vial with 1.8&nbsp;mL sodium chloride 9&nbsp;mg/mL (0.9%) solution
  for injection, using a 21&nbsp;gauge or narrower needle and aseptic
  techniques. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=268 height=332
  src="Comirnaty-h-5735-en_files/image004.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Equalise vial pressure before removing the
  needle from the vial stopper by withdrawing 1.8&nbsp;mL air into the empty
  diluent syringe.</span></p>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=245 height=335
  src="Comirnaty-h-5735-en_files/image005.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Gently invert the diluted dispersion
  10&nbsp;times. Do not shake.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>The diluted vaccine should present as an
  off-white dispersion with no particulates visible. Discard the diluted
  vaccine if particulates or discolouration are present.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=274 height=293
  src="Comirnaty-h-5735-en_files/image006.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>The diluted vials should be marked with the appropriate
  date and time.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Do not freeze or shake the diluted dispersion.
  If refrigerated, allow the diluted dispersion to come to room temperature
  prior to use.</span></p>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=2 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
  name="_Hlk48569403"><b><span lang=EN-GB>PREPARATION OF INDIVIDUAL 0.3&nbsp;mL
  DOSES OF COMIRNATY</span></b></a></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=254 height=264
  src="Comirnaty-h-5735-en_files/image007.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>After dilution, the vial contains 2.25&nbsp;mL
  from which </span><span lang=EN-GB>6</span><span lang=EN-GB> doses of
  0.3&nbsp;mL can be extracted. </span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span>Using aseptic technique, cleanse the vial stopper with a single&#8209;use
  antiseptic swab.</p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span>Withdraw 0.3&nbsp;mL of Comirnaty.</p>
  <p class=MsoNormal style='line-height:normal'>&nbsp;</p>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal'>Low dead&#8209;volume
  <span lang=EN-GB>syringes and/or needles should be used in order to extract
  6&nbsp;doses from a single vial. The low dead&#8209;volume syringe and needle
  combination should have a dead volume of no more than 35&nbsp;microlitres.</span></p>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal'>&nbsp;</p>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal'>If standard
  syringes and needles are used, there may not be sufficient volume to extract
  a sixth dose from a single vial.</p>
  <p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Each
  dose must contain 0.3&nbsp;mL of vaccine.</span></p>
  <p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
  the amount of vaccine remaining in the vial cannot provide a full dose of
  0.3&nbsp;mL, discard the vial and any excess volume.</span></p>
  <p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Discard
  any unused vaccine within 6&nbsp;hours after dilution</span>.</p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoListParagraph style='margin-left:.25in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Disposal</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>7.       MARKETING
AUTHORISATION HOLDER</span></b></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>BioNTech Manufacturing GmbH</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=DE>An der Goldgrube 12</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=DE>55131 Mainz</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=DE>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Phone: +49 6131 90840</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fax: +49 6131
9084390</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>info@biontech.de</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>8.       MARKETING
AUTHORISATION NUMBER(S) </span></b></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/20/1528</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>9.       DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></h1>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 21 December 2020</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>10.     DATE OF REVISION
OF THE TEXT</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed information
on this medicinal product is available on the website of the European Medicines
Agency </span><span lang=EN-GB><a href="http://www.ema.europa.eu"><span
style='color:windowtext;text-decoration:none'>http://www.ema.europa.eu</span></a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<h1 align=center style='margin-top:0in;text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>ANNEX
II</span></b></h1>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>A. </span></b><b><span lang=EN-GB>       </span><span
lang=EN-GB>MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><b><span lang=EN-GB>B. </span></b><b><span lang=EN-GB>        </span><span
lang=EN-GB>CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.95pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><b><span lang=EN-GB>C. </span></b><b><span lang=EN-GB>       </span><span
lang=EN-GB>OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:77.9pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>D.        <span style='text-transform:uppercase'>conditions
or restrictions with regard to the safe and effective use of the medicinal
product</span></span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>E.         SPECIFIC OBLIGATION TO COMPLETE POST&#8209;AUTHORISATION
MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION</span></b></p>

<span lang=EN-GB style='font-size:16.0pt;font-family:"Cambria",serif;
color:#365F91'><br clear=all style='page-break-before:always'>
</span>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
margin-bottom:.0001pt;text-indent:-28.35pt'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>A.      MANUFACTURERS
OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURERS RESPONSIBLE FOR BATCH
RELEASE</span></b></h1>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturers of
the biological active substance(s)</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>BioNTech
Manufacturing GmbH </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>An der Goldgrube 12
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>55131 Mainz</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Rentschler
Biopharma SE</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Erwin-Rentschler-Strasse
21</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>88471 Laupheim</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Wyeth BioPharma
Division of Wyeth Pharmaceuticals LLC </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>1 Burtt Road</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Andover, MA
01810</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>USA</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturers
responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>BioNTech
Manufacturing GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kupferbergterrasse
17 - 19</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>55116 Mainz</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Pfizer Manufacturing Belgium NV </span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Rijksweg 12 </span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>2870 Puurs </span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The printed
package leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In view of the declared Public Health Emergency
of International Concern and in order to ensure early supply this medicinal
product is subject to a time-limited exemption allowing reliance on batch
control testing conducted in the registered site(s) that are located in a third
country. This exemption ceases to be valid on 31&nbsp;August&nbsp;2021.
Implementation of EU based batch control arrangements, including the necessary
variations to the terms of the marketing authorisation, has to be completed by
31&nbsp;August&nbsp;2021 at the latest, in line with the agreed plan for this
transfer of testing. Progress reports have to be submitted on 31 March 2021 and
included in the annual renewal application.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
margin-bottom:.0001pt;text-indent:-28.35pt'><a name="OLE_LINK2"><b><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>B.</span></b></a><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>      CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE </span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to medical prescription.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Official
batch release</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>In accordance with Article 114 of Directive 2001/83/EC, the official
batch release will be undertaken by a state laboratory or a laboratory
designated for that purpose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
margin-bottom:.0001pt;text-indent:-28.35pt'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>C.      OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></h1>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Periodic
safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The requirements for submission of PSURs for this medicinal product
are set out in the list of Union reference dates (EURD list) provided for under
Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on
the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The marketing
authorisation holder (MAH) shall submit the first PSUR for this product within
6&nbsp;months following authorisation. </span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
margin-bottom:.0001pt;text-indent:-28.35pt'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>D.      CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></b></h1>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The </span><span lang=EN-GB>marketing authorisation
holder (</span><span lang=EN-GB>MAH) shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the marketing authorisation and any agreed subsequent updates of the
RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>At
the request of the European Medicines Agency;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the
benefit/risk profile or as the result of an important (pharmacovigilance or
risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
margin-bottom:.0001pt;text-indent:-28.35pt'><b><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>E.      SPECIFIC
OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL
MARKETING AUTHORISATION</span></b></h1>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>This being a conditional marketing authorisation and pursuant to
Article 14-a of Regulation (EC) No 726/2004, the MAH shall complete, within the
stated timeframe, the following measures:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="80%" valign=top style='width:80.82%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
   lang=EN-GB>Description</span></b></p>
   </td>
   <td width="19%" valign=top style='width:19.18%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><b><span
   lang=EN-GB>Due date</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="80%" valign=top style='width:80.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>In order to
  complete the characterisation of the active substance and finished product,
  the MAH should provide additional data. </span></p>
  </td>
  <td width="19%" valign=top style='width:19.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>July 2021.
  Interim reports: 31 March 2021</span></p>
  </td>
 </tr>
 <tr>
  <td width="80%" valign=top style='width:80.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>In order to
  ensure consistent product quality, the MAH should provide additional
  information to enhance the control strategy, including the active substance
  and finished product specifications.</span></p>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="19%" valign=top style='width:19.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>July 2021.
  Interim reports: March 2021</span></p>
  </td>
 </tr>
 <tr>
  <td width="80%" valign=top style='width:80.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>In order to
  confirm the consistency of the finished product manufacturing process, the
  MAH should provide additional validation data.</span></p>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="19%" valign=top style='width:19.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>March 2021</span></p>
  </td>
 </tr>
 <tr>
  <td width="80%" valign=top style='width:80.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>In order to
  confirm the purity profile and ensure comprehensive quality control and
  batch-to-batch consistency throughout the lifecycle of the finished product,
  the MAH should provide additional information about the synthetic process and
  control strategy for the excipient ALC-0315.</span></p>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="19%" valign=top style='width:19.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>July 2021.
  Interim reports: January 2021, April 2021</span></p>
  </td>
 </tr>
 <tr>
  <td width="80%" valign=top style='width:80.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>In order to
  confirm the purity profile and ensure comprehensive quality control and
  batch-to-batch consistency throughout the lifecycle of the finished product,
  the MAH should provide additional information about the synthetic process and
  control strategy for the excipient ALC-0159.</span></p>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="19%" valign=top style='width:19.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>July 2021.
  Interim reports: January 2021, April 2021</span></p>
  </td>
 </tr>
 <tr>
  <td width="80%" valign=top style='width:80.82%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>In order to confirm
  the efficacy and safety of Comirnaty, the MAH should submit the final
  Clinical Study Report for the randomized, placebo-controlled, observer-blind
  study C4591001.</span></p>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="19%" valign=top style='width:19.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TabletextrowsAgency style='line-height:normal'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>December 2023</span></p>
  </td>
 </tr>
</table>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>CARTON BOX LABEL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>COMIRNATY
concentrate for dispersion for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>COVID-19 mRNA
Vaccine (nucleoside modified)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After dilution
each vial contains 6 doses of 0.3&nbsp;mL.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients:
ALC-0315, ALC-0159, </span><span lang=EN-GB>DSPC</span><span lang=EN-GB>,
cholesterol, potassium chloride, potassium dihydrogen phosphate, sodium
chloride, disodium phosphate dihydrate, sucrose, water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concentrate for dispersion
for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>195 multidose
vials</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Intramuscular
use after dilution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Scan QR code for
more information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dilute before
use: Dilute each vial with 1.8&nbsp;mL sodium chloride 9&nbsp;mg/mL (0.9%)
solution for injection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Keep out of the sight and reach of children</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Storage: </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Prior to dilution, store at -90&nbsp;°C to -60&nbsp;°C</span><span
lang=EN-GB> in the original package in order to protect from light</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>After dilution, store the vaccine at 2&nbsp;°C to 30&nbsp;°C and use
within 6 hours. Discard any unused vaccine.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS
FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>11.     NAME AND ADDRESS OF
THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>BioNTech
Manufacturing GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>An der Goldgrube
12</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>55131 Mainz,
Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><b><span lang=EN-GB style='color:#1F497D'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/20/1528</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>LOT</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>17.     UNIQUE IDENTIFIER –
2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE IDENTIFIER -
HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO
APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>VIAL LABEL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>COMIRNATY
sterile concentrate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>COVID-19 mRNA
Vaccine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IM</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.       METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>LOT</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.       CONTENTS BY
WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>6 doses after dilution</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Discard date/time:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Comirnaty concentrate for dispersion for injection</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>COVID-19 mRNA Vaccine </span></b><b><span lang=EN-GB>(nucleoside
modified)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE><img border=0
width=21 height=18 id="Picture 2" src="Comirnaty-h-5735-en_files/image008.png"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicine is subject to
additional monitoring. This will allow quick identification of new safety
information. You can help by reporting any side effects you may get. See the
end of section 4 for how to report side effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Read all of this leaflet
carefully before you receive this vaccine because it contains important
information for you.</span></b></h1>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Keep
this leaflet. You may need to read it again. </span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you have </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>any</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> further questions, ask
your doctor, pharmacist or nurse.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you get any side effects, talk to your doctor, pharmacist or nurse. This
includes any po</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>ssible
side effects not listed in th</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>is
leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>What is in this leaflet</span></b></h1>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.    What Comirnaty is and what it is used for </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.    What you need to know before you receive Comirnaty</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.    How Comirnaty is given </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.    Possible side effects </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.    How to store Comirnaty</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.    Contents of the pack and other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>1.       What Comirnaty
is and what it is used for</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Comirnaty is a vaccine used for preventing COVID-19 caused by
SARS-CoV-2 virus. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Comirnaty is given to adults and adolescents from 16 years of age
and older. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The vaccine causes the immune system (the body’s natural defences)
to produce antibodies and blood cells that work against the virus, so giving
protection against COVID-19.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>As Comirnaty does not contain the virus to produce immunity, it cannot
give you COVID-19.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>2.       What you need to
know before you receive Comirnaty </span></b></h1>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Comirnaty
should not be given</span></b></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>if </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>you</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> are allergic to the active
substance or any of the other ingredients of this medicine (listed in section
6) </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Warnings and precautions</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor, pharmacist or nurse before you are given the vaccine if:</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>you
have ever had a severe allergic reaction or breathing problems after any other
vaccine injection or after</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>
you were given Comirnaty in the past.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>you
have ever fainted following any needle injection.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>you
have a </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>severe</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> illness or infection
with high fever. </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>However,
you can have your vaccination if you have a mild fever or upper airway
infection like a cold.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>you
have a bleeding problem, you bruise easily or you use a medicine to prevent
blood-clots.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>you
have a </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>weakened
immune system, because of a disease such as HIV infection or a medicine such as
corticosteroid that affects your immune system</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As with any vaccine, the 2-dose vaccination
course of Comirnaty may not fully protect all those who receive it and it is
not known how long you will be protected.</span></p>

<p class=MsoNormal style='margin-right:8.35pt;line-height:12.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Children and adolescents</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Comirnaty is not
recommended for children aged under 16 years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Other medicines and Comirnaty</span></b></h1>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tell your
doctor or pharmacist if you are using, have recently used or might use any
other medicines or have recently received any other vaccine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you are
pregnant or breast-feeding, think you may be pregnant or are planning to have a
baby, ask your doctor or pharmacist for advice before you receive this vaccine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Some of the
effects of vaccination mentioned in section 4 (Possible side effects) may
temporarily affect your ability to drive or use machines. Wait until these
effects have worn off before you drive or use machines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Comirnaty contains potassium and sodium</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This vaccine
contains less than 1 mmol potassium (39</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>mg) per dose, that is to say essentially ‘potassium-free’.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>This vaccine contains
less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially
‘sodium</span><span lang=EN-GB>&#8209;</span><span lang=EN-GB>free’.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>3.       How Comirnaty is
given</span></b></h1>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Comirnaty is given after dilution as an injection of 0.3&nbsp;mL
into a muscle of your upper arm.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You will receive 2</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>It is recommended to receive the second dose of
the same vaccine 3 weeks after the first dose to complete the vaccination course.
</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>If you have any
further questions on the use of Comirnaty, ask your doctor, pharmacist or
nurse.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><a name="_4._POSSIBLE_SIDE"></a><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>4.       Possible side
effects</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all vaccines, Comirnaty can cause side effects, although not
everybody gets them.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Very common </span></b><b><span lang=EN-GB>side
effects:</span></b><span lang=EN-GB> may affect more than 1 in 10 people</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>injection
site: pain, swelling </span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>tiredness</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>headache</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>muscle
pain </span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>joint
pain</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>chills,
fever</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Common side effects:</span></b><span lang=EN-GB> may affect up to 1
in 10 people</span></p>

<p class=MsoListParagraph style='margin-left:28.1pt;text-indent:-28.1pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>injection
site redness </span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>nausea</span></p>

<p class=MsoListParagraph><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Uncommon side effects:</span></b><span lang=EN-GB> may affect up to
1 in 100 people</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>enlarged
lymph nodes</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>feeling
unwell</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>pain
in limb</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>insomnia</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>injection
site itching</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Rare side effects: </span></b><span
lang=EN-GB>may affect up to 1 in 1,000 people</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>temporary
one sided facial drooping</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Not known </span></b><span
lang=EN-GB>(cannot be estimated from the available data) </span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>severe
allergic reaction </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Reporting of side effects</span></b></h1>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor, pharmacist or nurse. This includes
any possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:lightgrey'>Appendix
V</span></a></span><span class=MsoHyperlink><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'> </span></span><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>and include batch/Lot
number if available.</span><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'> By reporting side effects you can help provide more
information on the safety of this medicine.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>5.       How to store Comirnaty</span></b></h1>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep </span><span lang=EN-GB>this medicine </span><span lang=EN-GB>out
of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>The following information about storage, expiry and use and handling
is intended for healthcare professionals.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and label after EXP. The expiry date refers to the last day of that
month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in freezer at -90&nbsp;°C to -60&nbsp;°C<span
style='color:black'>.</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store in the original package in order to protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After thawing, the vaccine should be
diluted and used immediately. However, in-use stability data have demonstrated
that once removed from freezer, the undiluted vaccine can be stored for up to 5&nbsp;days
at 2&nbsp;°C to 8&nbsp;°C, or up to 2 hours at temperatures up to 30&nbsp;°C,
prior to use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After dilution, store the vaccine at 2&nbsp;°C
to 30&nbsp;°C and use within 6 hours. Discard any unused vaccine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Once removed from the freezer and diluted,
the vials should be marked with the new discard date and time. Once thawed, the
vaccine cannot be re-frozen.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this vaccine if you notice particulates
in the dilution or discolouration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>6.       Contents of the
pack and other information</span></b></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>What Comirnaty contains </span></b></h1>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
active substance is COVID-19 mRNA Vaccine. After dilution, the vial contains 6&nbsp;doses
of&nbsp;0.3&nbsp;mL with 30 micrograms mRNA each.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
other ingredients are: </span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)
(ALC-0315)</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>2-[(polyethylene
glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>1,2-Distearoyl-sn-glycero-3-phosphocholine
(DSPC)</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>cholesterol</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>potassium
chloride</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>potassium
dihydrogen phosphate</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>sodium
chloride</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>disodium
phosphate dihydrate</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>sucrose</span></p>

<p class=MsoListParagraph style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>water
for injections</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>What Comirnaty looks like
and contents of the pack</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>The vaccine is a white to off-white dispersion </span><span
lang=EN-GB>(pH: 6.9 - 7.9) </span><span lang=EN-GB style='color:black'>provided
in a multidose vial of 6&nbsp;doses in a 2&nbsp;mL clear vial (type I glass),
with a rubber stopper and a flip-off plastic cap with aluminium seal.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>Pack size: 195 vials</span></p>

<p class=MsoNormal><span lang=EN-GB> </span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Marketing Authorisation
Holder</span></b></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>BioNTech Manufacturing GmbH</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>An der Goldgrube 12</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>55131 Mainz</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phone: +49 6131
90840</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Fax: +49 6131
9084390</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>info@biontech.de</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Manufacturers</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>BioNTech
Manufacturing GmbH</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Kupferbergterrasse
17 - 19</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>55116 Mainz</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Germany </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer
Manufacturing Belgium NV </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=DE>Rijksweg 12 </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2870 Puurs </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Belgium</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b><span
  lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer S.A./N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tél/Tel: +32
  (0)2 554 62 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=DE>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer Luxembourg
  SARL filialas Lietuvoje</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel. +370 52
  51 4000</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1055;&#1092;&#1072;&#1081;&#1079;&#1077;&#1088;
  &#1051;&#1102;&#1082;&#1089;&#1077;&#1084;&#1073;&#1091;&#1088;&#1075;
  &#1057;&#1040;&#1056;&#1051;, &#1050;&#1083;&#1086;&#1085;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Te&#1083;:
  +359 2 970 4333</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Kft</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +36 1 488
  3700</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>&#268;eská
  republika</span></b></p>
  <p class=MsoNormal><span lang=DE>Pfizer, spol. s r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: +420 283 004
  111</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vivian
  Corporation Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +35621 344610</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer ApS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: +45 44
  201 100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer AS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: +47 67
  526 100</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='font-family:"Calibri",sans-serif'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>BioNTech Manufacturing GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +49 6131
  90840</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer BV</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +31 (0)10
  406 43 01<b> </b></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer Luxembourg
  SARL Eesti filiaal</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +372 666 7500</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer
  Corporation Austria Ges.m.b.H</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +43 (0)1
  521 15-0<b> </b></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer
  &#917;&#955;&#955;&#940;&#962; A.E.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#932;&#951;&#955;.:
  +30 210 6785 800</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer Polska Sp.
  z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel.: +48 22
  335 61 00<b> </b></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>España</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer, S.L.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Télf:+34914909900</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Biofarmacêutica,
  Sociedade Unipessoal Lda</span><span lang=EN-GB> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +351 21
  423 5500<b> </b></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tél +33 1 58
  07 34 40</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>România</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Romania
  S.R.L</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +40 (0)
  21 207 28 00<b> </b></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Croatia
  d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +385 1
  3908 777</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer
  Luxembourg SARL</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer,
  podružnica za svetovanje s podro&#269;ja</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>farmacevtske
  dejavnosti, Ljubljana</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel.: +386 (0)
  1 52 11 400<b> </b></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer
  Healthcare Ireland</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: 1800 633
  363 (toll free)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>+44 (0)1304
  616161</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Slovenská
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer Luxembourg
  SARL,</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>organiza&#269;ná
  zložka</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +421 2
  3355 5500<b> </b></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Icepharma hf</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Simi: +354 540
  8000</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer Oy</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Puh/Tel: +358
  (0)9 430 040<b> </b></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer S.r.l.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +39 06 33
  18 21</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Pfizer AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +46 (0)8
  550 520 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer
  &#917;&#955;&#955;&#940;&#962; &#913;.&#917;. (Cyprus Branch)</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T&#951;&#955;:
  +357 22 817690</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom (Northern Ireland)</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pfizer Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 (0)
  1304 616161</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Pfizer Luxembourg
  SARL fili&#257;le Latvij&#257;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel.: +371 670
  35 775</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in {MM/YYYY}</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicine has been given ‘conditional
approval’. This means that there is more evidence to come about this medicine.
The European Medicines Agency will review new information on this medicine at
least every year and this leaflet will be updated as necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Scan the code with a mobile device to get the package leaflet in
different languages.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=DE><img
border=0 width=130 height=130 id="Picture 5"
src="Comirnaty-h-5735-en_files/image009.png"></span><span lang=DE> </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>URL: <a href="http://www.comirnatyglobal.com"><span
style='color:windowtext;text-decoration:none'>www.comirnatyglobal.com</span></a>
</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: http://www.ema.europa.eu. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This package leaflet is available in all EU/EEA languages on the
European Medicines Agency website.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>------------------------------------------------------------------------------------------------------------------------</span></p>

<p class=MsoNormal style='margin-right:-1.4pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>The following information
is intended for healthcare professionals only:</span></b></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Administer Comirnaty intramuscularly after dilution as a course of 2
doses (0.3&nbsp;mL each) 3&nbsp;weeks apart.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Traceability </span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In order to improve the traceability of biological medicinal
products, the name and the batch number of the administered product should be
clearly recorded. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Handling instructions</span></b></h1>

<p class=MsoNormal><span lang=EN-GB>Comirnaty should be prepared by a
healthcare professional using aseptic technique to ensure the sterility of the
prepared dispersion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=TableGrid1 border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=2 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>THAWING PRIOR TO DILUTION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=305 height=166
  src="Comirnaty-h-5735-en_files/image010.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>The multidose vial is stored frozen and must
  be thawed prior to dilution. Frozen vials should be transferred to an
  environment of 2&nbsp;°C to 8&nbsp;°C to thaw; a 195&nbsp;vial pack may take
  3&nbsp;hours to thaw. Alternatively, frozen vials may also be thawed for
  30&nbsp;minutes at temperatures up to 30&nbsp;°C for immediate use.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Allow the thawed vial to come to room
  temperature and gently invert it 10&nbsp;times prior to dilution. Do not
  shake.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Prior</span><span lang=EN-GB> to dilution, the
  thawed dispersion may contain white to off-white opaque amorphous particles. </span></p>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=2 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>DILUTION</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=299 height=288
  src="Comirnaty-h-5735-en_files/image011.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-size:12.0pt;font-family:Symbol;
  color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>The thawed vaccine must be diluted in its
  original vial with 1.8&nbsp;mL sodium chloride 9&nbsp;mg/mL (0.9%) solution
  for injection, using a 21&nbsp;gauge or narrower needle and aseptic
  techniques. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=268 height=332
  src="Comirnaty-h-5735-en_files/image004.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Equalise vial pressure before removing the
  needle from the vial stopper by withdrawing 1.8&nbsp;mL air into the empty
  diluent syringe.</span></p>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=245 height=335
  src="Comirnaty-h-5735-en_files/image012.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Gently invert the diluted dispersion
  10&nbsp;times. Do not shake.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>The diluted vaccine should present as an off-white
  dispersion with no particulates visible. Discard the diluted vaccine if
  particulates or discolouration are present.</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-size:12.0pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=274 height=293
  src="Comirnaty-h-5735-en_files/image013.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>The diluted vials should be marked with the appropriate
  date and time.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Do not freeze or shake the diluted dispersion.
  If refrigerated, allow the diluted dispersion to come to room temperature
  prior to use.</span></p>
  <p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=2 valign=top style='width:453.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>PREPARATION OF INDIVIDUAL 0.3&nbsp;mL DOSES OF COMIRNATY</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=330 valign=top style='width:247.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DE style='font-family:
  "Calibri",sans-serif'><img border=0 width=254 height=264
  src="Comirnaty-h-5735-en_files/image014.png"></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=274 valign=top style='width:205.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>After dilution, the vial contains 2.25&nbsp;mL
  from which 6&nbsp;doses of 0.3&nbsp;mL can be extracted. </span></p>
  <p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Using
  aseptic technique, cleanse the vial stopper with a single-use antiseptic swab.</span></p>
  <p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
  normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>Withdraw 0.3&nbsp;mL of Comirnaty. </span></p>
  <p class=MsoNormal><span style='font-family:"Calibri",sans-serif;background:
  yellow'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB>Low dead-volume
  syringes and/or needles should be used in order to extract 6 doses from a
  single vial. The low dead&#8209;volume syringe and needle combination should
  have a dead volume of no more than 35&nbsp;microlitres</span><span
  style='font-family:"Calibri",sans-serif'>.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB>If standard
  syringes and needles are used, there may not be sufficient volume to extract
  a sixth dose from a single vial.</span></p>
  <p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Each
  dose must contain 0.3&nbsp;mL of vaccine.&nbsp; </span></p>
  <p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
  the amount of vaccine remaining in the vial cannot provide a full dose of
  0.3&nbsp;mL,&nbsp;discard the vial and any excess volume. </span></p>
  <p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
  lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Discard
  any unused vaccine within 6&nbsp;hours after dilution</span>.</p>
  <p class=MsoNormal style='line-height:normal'><span style='font-size:10.5pt;
  font-family:"Segoe UI",sans-serif'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><b><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'>Disposal</span></b></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements. </span></p>

</div>

</body>

</html>
